Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

ls and communications pathways in cancer, we are improving our ability to effectively treat the disease while avoiding the toxicities of chemotherapy and potential relapse," said John C. Byrd, MD, lead author and Director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute in Columbus. "If we can replicate these high survival rates and good tolerability with ibrutinib through larger scale Phase III studies, we may find it to be an extremely valuable new therapy for not just elderly, but for all CLL patients."

Dr. Byrd will present this study in an oral presentation on Sunday, December 9, at 5:00 p.m. EST at the Georgia World Congress Center in Thomas Murphy Ballroom 4, Level 5, Building B.

The BTK Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab is Well−Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients [Abstract 187]

The combination of the novel investigational agent ibrutinib with an established therapeutic antibody, rituximab, may present a safer and more effective option than the current standard chemotherapy-based treatment regimen for patients with high-risk CLL.

While current chemotherapy-based treatment options for CLL patients are effective, they come with toxic side effects that are challenging for elderly patients. Physicians have long awaited new options that offer better tolerability. Ibrutinib is designed to selectively target leukemia cell growth, with the aim of effectively treating the disease without the toxicities of chemotherapy. Data from earlier studies of ibrutinib have shown it to be equally effective in both low- and high-risk CLL.

High-risk CLL patients typically have unfavorable responses to standard CLL therapies and a dismal outcome. S
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014 (HealthDay News) -- Some people with ... implant,s internal magnet when they undergo an MRI scan, ... supplied by the researchers, about 300,000 people worldwide have ... to people who are deaf or have severe hearing ... people with cochlear implants when undergoing MRI. One ...
(Date:11/21/2014)... Serena Gordon HealthDay ... Two U.S. government agencies have proposed new rules that ... clinical trial was successful or not. The proposed ... to publish summaries of their results to ClinicalTrials.gov -- a ... Health (NIH) and the U.S. Department of Health and Human ...
(Date:11/21/2014)... They</i> Need a Kidney" style="border-width:0px;" /> THURSDAY, Nov. 20, 2014 ... most selfless acts one person can do for another. And ... they need a kidney later in life are benefiting from ... Living donors provided organs for almost 6,300 of the ... in 2010, according to background information supplied by the study ...
(Date:11/18/2014)... 2014 On November 18, 2014, My ... Tails magazine publisher Keith Simmons for an episode. At ... “You also are the publisher of the Traveler Charleston ... one another?” Simmons responds, “Our company is Traveler Communication ... is Traveler Charleston and then we custom publish a ...
(Date:11/18/2014)... 2014 Examination Management Services, Inc. ... management and investigative services, has launched a proprietary ... to enhance its paramedical exam service to life ... use of EMSI’s 5 Star Examiner Performance Model, ... paramedical exams are conducted by examiners whose performance ...
Breaking Medicine News(10 mins):Health News:MRI Can Be Painful, Disruptive for People With Cochlear Implants 2Health News:U.S. Proposes Greater Public Access to Data From Clinical Trials 2Health News:Study Supports Giving Kidney Donors Priority When They Need a Kidney 2Health News:My Positive Perspective Broadcasts Episode Discussing Animal Rights and Carolina Tails Magazine 2Health News:EMSI Launches Proprietary 5 Star Examiner Performance Model to Enhance Paramedical Exam Service 2
... to particular product brands,when their level of anxiety ... study in the, Journal of Consumer Research . ... Korea,University), James E. Burroughs (University of Virginia), and ... and insecurity,in consumers and discovered that the combination ...
... 2009) There is hope that the drug rasagiline can ... -- slow the progression of a devastating degenerative brain disease ... function. , Now a new study looking at the ... that people who began the drug earlier continued to do ...
... Ariz., Jan. 26 The Providence Service ... Center on Budget and Policy Priorities, preliminary analysis of ... package. The report was issued on January 22, ... is one of the nation,s premier policy organizations working ...
... you can get a more aggressive treatment for facial ... Calif., Jan. 26 The Pearl procedure is used ... skin and aging to provide a healthy, pearl-like glow. ... selected pattern, the laser concurrently sends heat to the ...
... Students across the,country will soon kick off Olive ... Leukemia & Lymphoma Society,s (LLS) School,& Youth campaign. ... ) , A ... and school,administrators, Pasta for Pennies has raised more ...
... CIGNA using incentives to foster healthy choices.LYNDHURST, N.J., ... integrated incentive solutions to the healthcare industry, announced ... has launched a new "points-based" health incentive program ... will offer employers ways to motivate their employees ...
Cached Medicine News:Health News:Security blankets: Materialism and death anxiety lead to brand loyalty 2Health News:Patients starting Parkinson's drug rasagiline earlier do better 2Health News:Providence Service Corporation Provides The Center on Budget and Policy Priorities' Preliminary Analysis of Potential Medicaid Assistance for States in the House Economic Recovery Package 2Health News:Providence Service Corporation Provides The Center on Budget and Policy Priorities' Preliminary Analysis of Potential Medicaid Assistance for States in the House Economic Recovery Package 3Health News:Renaissance Laser & Vein Institute (LaserandVeinclinic.com) 'Pearl Treatment' 2Health News:Olive Garden's Pasta for Pennies Makes Cents for Cancer Research 2Health News:IncentOne Provides Incentive Solution to CIGNA 2
(Date:11/21/2014)... 20, 2014   Wellcentive , the industry ... healthcare organizations, announced today being named one of ... Innovation Award .  Sponsored by Intel, the world ... fourth year, recognizes companies developing leading-edge technology and ... processes. Wellcentive,s Mason Beard ...
(Date:11/18/2014)... , Nov. 18, 2014  Sanguine Biosciences – ... engagement and study recruitment – will use its ... to help Pfizer Inc. find and recruit people ... their family members to participate in voluntary research, ... DNA mutations and hopefully aid in informing the ...
(Date:11/18/2014)... -- BioLink 2015, the BioPh & ICSE BioPharm ... CCCMHPIE ( China Chamber of Commerce for ... UBM Live and Beijing Yizhuang Biomedical Park, will ... Yizhuang Biomedical Park.   ... will gather 200+ decision makers from biopharmaceutical industrial players ...
Breaking Medicine Technology:Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2BioLink 2015 Will be Held on Jan 22, 2015, with a Focus on Biopharma Industrial Innovation & International Technology Transfer 2BioLink 2015 Will be Held on Jan 22, 2015, with a Focus on Biopharma Industrial Innovation & International Technology Transfer 3
... Fla., Dec. 29 Connectyx Technologies Holdings Group, Inc. (Other ... RV Owners Community as a marketing partner to its MedFlash ... million members and more than 3,400 individual club chapters and ... Club provides its membership with essential services ranging from towing ...
... , REDWOOD CITY, Calif., Dec. 28 Codexis, Inc. announced today ... the U.S. Securities and Exchange Commission ("SEC") relating to the proposed ... shares of common stock to be sold in this offering are ... stockholders. , Credit Suisse Securities (USA) LLC and Goldman, Sachs & ...
Cached Medicine Technology:Connectyx Announces MedFlash Sales Partnership with National Recreational Vehicle Club 2Connectyx Announces MedFlash Sales Partnership with National Recreational Vehicle Club 3Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Celestial Star™ light is ... The flexible design allows ... positioning. The space-saving structure ... facilities including emergency rooms, ...
The Next Generation in Single Lamp Technology, Advanced Optics & Reflector Design, Extended Depth of Field, 54" Useable Column of Light, High Intensity, Cool Beam Temperature...
... its introduction to the market, the U100 ... proven itself as a highly efficient and ... of urology and gastroenterology. The new U100Plus ... technically further developed and improved in many ...
ELVeS™ (Endo Laser Vein System) from biolitec is a versatile, easy to use & complete system that allows you to treat all conditions resulting from venous incompetence. (ELVeS has FDA clearance ...
Medicine Products: